Literature DB >> 30830586

Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation.

Anastasios Kartas1, Athanasios Samaras1,2, Dimitra Vasdeki1, George Dividis1, George Fotos1, Eleni Paschou1, Evropi Forozidou1, Paraskevi Tsoukra1, Eleni Kotsi1, Ioannis Goulas1, George Efthimiadis1, Gregory Giamouzis3, Haralambos Karvounis1, Apostolos Tzikas1,4, George Giannakoulas5.   

Abstract

Scarce data are available on the effects of hospitalization on oral anticoagulation (OAC) patterns in patients with atrial fibrillation (AF). This study aimed to capture the evolving OAC patterns of patients with known non-valvular AF at high risk for stroke (CHA2DS2-Vasc score ≥ 2 for males and ≥ 3 for females) during hospitalization. A total of 561 eligible patients who were admitted to the cardiology ward of a tertiary hospital were studied. Pre- and post-hospitalization OAC patterns [vitamin-K antagonist (VKA), non-vitamin K oral anticoagulants (NOAC), no OAC], changes between these patterns (initiation, switch, discontinuation, no change) and the respective patient profiles and discharge diagnoses were assessed. During hospitalization, OAC administration increased from 73.1 to 86.6% of patients (p for trend < 0.001). NOAC use increased significantly (42.2-56.1%, p for trend < 0.001), whereas VKA use remained stable (30.8-30.5%). Of patients, 17.3% initiated OAC, 7.1% switched between OACs, 3.7% discontinued OAC treatment, while the rest underwent no change in anticoagulation status. Bleeding risk, use of concomitant antiplatelet therapy and incidence of primary discharge diagnosis of AF or ST-elevation myocardial infarction differed significantly between groups of initiation, switch, discontinuation and no change in OAC therapy. In conclusion, in patients with known AF at high risk for stroke, hospitalization was associated with an increase in OAC uptake, driven mainly by NOAC initiation. Three out of 10 patients initiated, switched or discontinued OAC treatment during hospitalization and this was associated with discrete epidemiologic parameters.

Entities:  

Keywords:  Atrial fibrillation; Hospitalization; Non-vitamin K oral anticoagulants; Oral anticoagulation patterns; Real world; Switch

Mesh:

Substances:

Year:  2019        PMID: 30830586     DOI: 10.1007/s11239-019-01832-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.

Authors:  Lars J Kjerpeseth; Hanne Ellekjær; Randi Selmer; Inger Ariansen; Kari Furu; Eva Skovlund
Journal:  Eur J Clin Pharmacol       Date:  2017-07-22       Impact factor: 2.953

3.  Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry.

Authors:  David F Katz; Thomas M Maddox; Mintu Turakhia; Anil Gehi; Emily C O'Brien; Steven A Lubitz; Alexander Turchin; Gheorghe Doros; Lanyu Lei; Paul Varosy; Lucas Marzec; Jonathan C Hsu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-05

4.  International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.

Authors:  Benjamin A Steinberg; Haiyan Gao; Peter Shrader; Karen Pieper; Laine Thomas; A John Camm; Michael D Ezekowitz; Gregg C Fonarow; Bernard J Gersh; Samuel Goldhaber; Sylvia Haas; Werner Hacke; Peter R Kowey; Jack Ansell; Kenneth W Mahaffey; Gerald Naccarelli; James A Reiffel; Alexander Turpie; Freek Verheugt; Jonathan P Piccini; Ajay Kakkar; Eric D Peterson; Keith A A Fox
Journal:  Am Heart J       Date:  2017-08-24       Impact factor: 4.749

Review 5.  Why switch from warfarin to NOACs?

Authors:  Paolo Verdecchia; Fabio Angeli; Adolfo Aita; Claudia Bartolini; Gianpaolo Reboldi
Journal:  Intern Emerg Med       Date:  2016-03-14       Impact factor: 3.397

6.  High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.

Authors:  Beenish S Manzoor; Surrey M Walton; Lisa K Sharp; William L Galanter; Todd A Lee; Edith A Nutescu
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

7.  Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF.

Authors:  Adam D DeVore; Anne S Hellkamp; Richard C Becker; Scott D Berkowitz; Guenter Breithardt; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C Nessel; Daniel E Singer; Keith A A Fox; Manesh R Patel; Jonathan P Piccini
Journal:  Europace       Date:  2016-05-12       Impact factor: 5.214

8.  The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey.

Authors:  Tatjana S Potpara; Elina Trendafilova; Gheorghe-Andrei Dan; Artan Goda; Zumreta Kusljugic; Sime Manola; Ljilja Music; Viktor Gjini; Belma Pojskic; Mircea Ioakim Popescu; Catalina Arsenescu Georgescu; Elena S Dimitrova; Delyana Kamenova; Uliks Ekmeciu; Denis Mrsic; Ana Nenezic; Sandro Brusich; Srdjan Milanov; Ivan Zeljkovic; Gregory Y H Lip
Journal:  Adv Ther       Date:  2017-08-09       Impact factor: 3.845

9.  Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort.

Authors:  Clara L Rodríguez-Bernal; Isabel Hurtado; Aníbal García-Sempere; Salvador Peiró; Gabriel Sanfélix-Gimeno
Journal:  Front Pharmacol       Date:  2017-02-17       Impact factor: 5.810

10.  Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.

Authors:  Laetitia Huiart; Cyril Ferdynus; Christel Renoux; Amélie Beaugrand; Sophie Lafarge; Léa Bruneau; Samy Suissa; Olivier Maillard; Xavier Ranouil
Journal:  BMJ Open       Date:  2018-03-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.